Home Categories Biochemical Engineering CAL-101
A2461612

CAL-101 , ≥99% , 870281-82-6

CAS NO.:870281-82-6

Empirical Formula: C22H18FN7O

Molecular Weight: 415.42

MDL number: MFCD19443647

EINECS: 807-438-9

Pack Size Price Stock Quantity
10MG RMB143.20 In Stock
50MG RMB219.20 In Stock
100MG RMB463.20 In Stock
250MG RMB736.00 In Stock
500MG RMB3140.80 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 250-252oC
Boiling point: 733.4±70.0 °C(Predicted)
Density  1.47
storage temp.  -20°C
solubility  Soluble in DMSO (>25 mg/ml)
form  White solid.
pka 10.00±0.10(Predicted)
color  White
Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.
InChIKey IFSDAJWBUCMOAH-HNNXBMFYSA-N
SMILES N1C2=C(C(F)=CC=C2)C(=O)N(C2=CC=CC=C2)C=1[C@@H](NC1=C2C(=NC=N1)NC=N2)CC

Description and Uses

Idelalisib (CAS 870281-82-6) is a potent (IC50 = 2.5nM) and selective (IC50’s: PI3Ka = 820nM, PI3Kb = 565nM, PI3Kg = 89nM) PI3Kd inhibitor.1,2 Useful clinical agent for the treatment of various blood cancers. Idelalisib attenuates regulatory T cells (Treg) but not conventional T cells (Tconv) resulting in a significant increase in tumor-infiltrating antigen-specific CD8 T cells in a murine lung cancer model.3 Conversely, systemic PI3Kd inactivation antagonized anti-CTLA-4 and anti-PD-L1 treatment.4 Others have found that Idelalisib minimally influenced rituximab- and obinutuzumab-mediated Ab-dependent cellular cytotoxicity in human lymphoma cells.5

CAL-101 is a PI3K/mTOR pathway inhibitor used in the treatment of myeloid leukemia through sensitizing the cells to combatting drugs. Potent PI3K-p110-delta inhibitor.

Safety

Symbol(GHS) 
GHS08
Signal word  Danger
Hazard statements  H372
Precautionary statements  P260-P264-P270-P314-P501
Safety Statements  V
HS Code  29399990
Hazardous Substances Data 870281-82-6(Hazardous Substances Data)

RELATED PRODUCTS